According to our latest research offering “ Asia Pacific Biotechnology Market (2008-2012)”, the Asia Pacific region is increasingly becoming the hub of global biotechnology industry due to favorable factors, such as vast population, rising prevalence of diseases, and increasing regulatory support. As a result of the supportive factors, the multinational companies have been investing in the region by promoting research work and increasing production capabilities. Due to these factors, it is expected that the Asia Pacific biotechnology market will grow at an incredible CAGR of around 16% during 2010-2012.
The most lucrative countries of the Asia Pacific region include Japan and China, with countries, such as India, Singapore, and Malaysia developing at a fast pace. It is estimated that, these emerging markets will occupy the lion’s share in the biotechnology market in near future. The main reason for the prominence of these markets can be attributed to the rising demand of biosimilar drugs, which are more affordable. Moreover, these drugs are being developed for a wide range of diseases and have been found to be more effective than the chemical based drugs.
Our team of experienced industry experts has provided information regarding every important aspect of the biotechnology industry in the Asia Pacific region. The report also includes detail discussions on the emerging market segments, including contract research and manufacturing, bioinformatics, and generics. Besides, the report contains detail overview of the various countries in the region, along with their market potential and future growth prospects.
Moreover, our report “Asia Pacific Biotechnology Market (2008-2012)” provides prudent analysis of the authentic data, which has been procured through extensive research. The forecasting has been done with due consideration of the impact of recent economic downturn and recovery period. The report also contains detail analysis and statistics of the segmentation, geographic distribution, trends in technology development, and competitive analysis of each country. The report provides valuable information to pharmaceutical & biotechnology companies and investors, which will help them in entering these markets with robust strategies.
For more information visit: http://www.rncos.com/Report/IM138.htm |
